Lupin has informed that it enclosed a Press Release titled ‘Lupin Launches Risperidone Long-Acting Injectable with 180- day CGT exclusivity in the U.S., the First Product from its Proprietary Long-Acting Injectable Platform PrecisionSphere’.
The above information is a part of company’s filings submitted to BSE.